Products for Research Use Only

LSD1/HDAC6-IN-2

CAT: 0804-HY-164099-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-164099-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
LSD1/HDAC6-IN-2 (JBI-802) is an orally active LSD1/HDAC6/MAO-A inhibitor, with IC50 values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma[1][2].
CAS Number
2982787-50-6
UNSPSC
12352005
Target
HDAC; Histone Demethylase; Monoamine Oxidase
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lsd1-hdac6-in-2.html
Purity
99.66
Solubility
DMSO : ≥ 100 mg/mL
Smiles
ONC(C(C=C1)=CC=C1CN(N=C2)C=C2CN[C@H]3[C@H](C4=CC=CC=C4)C3)=O.[H]Br
Molecular Formula
C21H23BrN4O2
Molecular Weight
443.34
References & Citations
[1]Yang X. Research progress of LSD1-based dual-target agents for cancer therapy. Bioorg Med Chem. 2024 Mar 1;101:117651. |[2]Sivanandhan D, et al. JBI-802, novel dual inhibitor of LSD1-HDAC6 for treatment of cancer[J]. Cancer Research, 2020, 80 (16_Supplement) : 1756-1756.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC6; KDM1/LSD1; MAO-A; MAO-B